AEGEAN Trial: Perioperative Approach in NSCLC
Tina Cascone, MD, PhD, analyzes results from the AEGEAN trial evaluating perioperative immunotherapy in stage II-IIIB non-small cell lung cancer.
This is a video synopsis/summary of a Precision Medicine featuring Patrick Forde, MBBCh, and Tina Cascone, MD, PhD.
Forde and Cascone discuss the AEGEAN study, a phase 3 trial that tested the combination of perioperative durvalumab, a PD-L1 inhibitor, with neoadjuvant platinum-based chemotherapy for patients with stage IA to IIIB non–small cell lung cancer (NSCLC) according to the American Joint Committee on Cancer 8th edition staging system. The trial aimed to induce greater pathological responses, improve outcomes, and potentially trigger immunological memory by administering immunotherapy in the perioperative setting.
In the AEGEAN trial, patients received 4 cycles of neoadjuvant chemotherapy plus durvalumab, followed by 12 cycles of adjuvant durvalumab, compared with neoadjuvant chemotherapy alone followed by adjuvant placebo. The study demonstrated an improvement in event-free survival with a hazard ratio of 0.68 in favor of durvalumab, as well as an improvement in the pathological complete response rate (17.2%) compared with chemotherapy alone.
The different criteria used for pathological response assessment in the AEGEAN trial compared with other studies, such as CheckMate 816 (which reported a 24% pathological complete response rate), highlight the need for harmonization of these criteria as these therapies become the standard of care.
Video synopsis is AI-generated and reviewed by Targeted Oncology™ editorial staff.
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
